Ipsen says FDA extending review date for Reloxin

January 14, 2009

Chicago - Ipsen says the Food and Drug Administration (FDA) is extending the initial drug review for Reloxin (botulinum toxin type A) to April 13, 2009, Reuters reports.

Chicago

- Ipsen says the Food and Drug Administration (FDA) is extending the initial drug review for Reloxin (botulinum toxin type A) to April 13, 2009, Reuters reports.

Ipsen also says the FDA confirmed the manufacturing process for the product in the Wales facility is in compliance, according to Reuters.